Why the study?
Does a 1-hour infusion of recombinant human atrial natriuretic peptide (rhANP) improve dyspnea and reduce pulmonary capillary wedge pressure in patients with acute decompensated heart failure?
RCT (n=477)
Double-blind
Random blocks of size 4, 3:1 ratio
Yes
Does a 1-hour infusion of recombinant human atrial natriuretic peptide (rhANP) improve dyspnea and reduce pulmonary capillary wedge pressure in patients with acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
A 1-hour infusion of rhANP in acute decompensated heart failure provides prompt, transient hemodynamic improvement but does not significantly improve dyspnea at 12 hours compared to standard therapy alone.
The aim of the study was to evaluate the efficacy and safety of 1-h infusion of recombinant human atrial natriuretic peptide (rhANP) in combination with standard therapy in patients with acute decompensated heart failure (ADHF). This was a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Eligible patients with ADHF were randomized to receive a 1-h infusion of either rhANP or placebo at a ratio of 3:1 in combination with standard therapy. The primary endpoint was dyspnea improvement (a decrease of at least 2 grades of dyspnea severity at 12 h from baseline). Reduction in pulmonary capillary wedge pressure (PCWP) 1 h after infusion was the co-primary endpoint for catheterized patients. Overall, 477 patients were randomized: 358 (93 catheterized) patients received rhANP and 118 (28 catheterized) received placebo. The percentage of patients with dyspnea improvement at 12 h was higher, although not statistically significant, in the rhANP group than in the placebo group (32.0% vs 25.4%, odds ratio=1.382, 95% confidence interval [CI]: 0.863-2.212, P = 0.17). Reduction in PCWP at 1 h was significantly greater in patients treated with rhANP than in patients treated with placebo (-7.74 ± 5.95 vs -1.82 ± 4.47 mm Hg, P < 0.001). The frequencies of adverse events and renal impairment within 3 days of treatment were similar between the 2 groups. Mortality at 1 month was 3.1% in the rhANP group vs 2.5% in the placebo group (hazard ratio = 1.21, 95% CI: 0.34-4.26; P > 0.99). 1-h rhANP infusion appears to result in prompt, transient hemodynamic improvement with a small, nonsignificant, effect on dyspnea in ADHF patients receiving standard therapy. The safety of 1-h infusion of rhANP seems to be acceptable. (WHO International Clinical Trials Registry Platform [ICTRP] number, ChiCTR-IPR-14005719.).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) conducted an RCT in Acute Decompensated Heart Failure (n=477). Recombinant human atrial natriuretic peptide (rhANP) vs. Placebo was evaluated on Dyspnea improvement (decrease of at least 2 grades of dyspnea severity at 12 h from baseline) (OR 1.382, 95% CI 0.863-2.212, p=0.17).
Synapse has enriched 10 related papers. Consider them for comparative context: